Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma
NCT05025423Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jun 2022; status: terminated.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05025423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025423.